Glaxo is acquiring GNLB for $1.30/share, with the deal to close in December, and GNLB is trading for $1.22 as I write this. Considering how small the purchase price ($57M) is compared to what's on GSK's balance sheet, it's hard to imagine how this doesn't go through, and you're getting a respectable 6.56% in 1-2 months.http://biz.yahoo.com/bw/081029/20081029006599.html(Disclosure: long GNLB (and wishing I was long yesterday...))
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings